FDA approves first generic of ProAir HFA | FDA

FDA approves first generic of ProAir HFA | FDA

FDA approves first generic of ProAir HFA (albuterol sulfate) inhalation aerosol

The U.S. Food and Drug Administration approved the first generic of ProAir HFA (albuterol sulfate) Inhalation Aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The most common side effects associated with Albuterol Sulfate Inhalation Aerosol are headache, rapid heart rate (tachycardia), pain, dizziness, sore throat (pharyngitis), rhinitis, chest pain, palpitations, tremor and nervousness.

Read More